The objectives of this proposal are to provide the applicant with intensive training in the areas of inflammation and lipidology and to advance applicant's research skills and expertise so as to facilitate his development as an independent investigator. The candidate will be mentored by established investigators and a multidisciplinary advisory committee and will pursue a program of education (coursework, conferences, and seminars) and a research project addressing the protective mechanisms by which an HDLmimetic peptide attenuates lipopolysaccharide (LPS)-mediated sepsis. Sepsis is a major health problem. 25- 30% of all cases of sepsis is due to gram negative bacterial (GNB) infection. LPS, a component of the outer membrane of GNB, mediates many of the toxic effects associated with sepsis. Results indicate that HDL administration may be effective in treating sepsis. However obtaining therapeutic quantities of the HDL is impractical. One mechanism by which HDL neutralizes LPS is thought to occur by insertion and masking of the lipid A domain of LPS into the phospholipid leaflet that covers the surface of HDL. This may occur due to complementary molecular shape of apo A-l (a major protein constituent of HDL) and the lipid A component of LPS. We have developed a novel peptide whose design is based on the structure of apo A-l. This peptide 4F is a class A amphipathic helical molecule that has many of the anti-atherosclerotic properties of apo A-l. Beneficial effects of 4F are thought to be due to its ability to modulate HDL properties including formation of pre-beta HDL like particles. We have observed that the molecular shape of 4F is complementary to that of lipid A. In this application, we demonstrate that administration of 4F significantly reduces LPS-induced activation of inflammatory cytokines and adhesion molecules both in-vitro and in-vivo. We propose the novel hypothesis that the apo A-l mimetic peptide 4F inhibits LPS induced inflammatory processes and will test whether this response is due to : i) Direct physical interaction between lipid A and 4F;ii) Indirect effects of 4F, by promoting the formation of apo A-l rich pre-beta HDL-like particles and thus enhancing the LPS scavenging capacity of HDL. This study will have important implications in understanding the role of apo A-l and HDL in LPS mediated sepsis. It will also provide a rationale for developing HDL-mimetic peptides as effective therapeutic agents against sepsis/inflammation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HL085282-04
Application #
7656610
Study Section
Special Emphasis Panel (ZHL1-CSR-O (M1))
Program Officer
Commarato, Michael
Project Start
2006-09-18
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
4
Fiscal Year
2009
Total Cost
$126,549
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Sharifov, Oleg F; Xu, Xin; Gaggar, Amit et al. (2014) L-4F inhibits lipopolysaccharide-mediated activation of primary human neutrophils. Inflammation 37:1401-12
Sharifov, Oleg F; Nayyar, Gaurav; Ternovoy, Vladimir V et al. (2014) Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A. Innate Immun 20:867-80
Sharifov, Oleg F; Xu, Xin; Gaggar, Amit et al. (2013) Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis. PLoS One 8:e64486
Sharifov, Oleg F; Nayyar, Gaurav; Ternovoy, Vladimir V et al. (2013) Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats. Biochem Biophys Res Commun 436:705-10
Sharifov, Oleg F; Nayyar, Gaurav; Garber, David W et al. (2011) Apolipoprotein E mimetics and cholesterol-lowering properties. Am J Cardiovasc Drugs 11:371-81
Datta, Geeta; Gupta, Himanshu; Zhang, Zhenghao et al. (2011) HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats. J Clin Exp Cardiolog 2:
Dai, Lijun; Datta, Geeta; Zhang, Zhenghao et al. (2010) The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J Lipid Res 51:2695-705
Datta, Geeta; White, C Roger; Dashti, Nassrin et al. (2010) Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Atherosclerosis 208:134-41
White, C Roger; Datta, Geeta; Mochon, Paulina et al. (2009) Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.). Vasc Dis Prev 6:122-130